Merck barred from making subcutaneous Keytruda in 8 European countries
A Dutch court blocked Merck from producing and selling its subcutaneous Keytruda formulation in 8 European countries, ruling it infringes a Halozyme Therapeutics patent. Merck argued the patent is invalid, but the court rejected this. The decision follows a similar ruling in Germany. Merck's intravenous Keytruda remains unaffected, generating $7.9 billion in Q2, while the subcutaneous version contributed $463 million.
How this was made
The 30-second read
Why it matters
The injunction curtails Merck's SC launch, preserving Halozyme's licensing power.
Market read
Regulatory/legal news with direct impact on two listed pharma stocks.
What to watch
Potential appeal outcomes in Germany and the U.K. could reverse the block.
Background
Merck's Keytruda SC was approved in Europe in November; Halozyme's Enhanze technology is used by several pharma firms.
Ticker impact
Dutch court blocked Merck from producing and selling subcutaneous Keytruda in eight European countries.
downward pressure as market prices in the regulatory setback.
The injunction affects a key growth product, reducing near‑term revenue potential.
Halozyme's Enhanze patent was upheld, leading to the injunction against Merck.
upward pressure as market sees strengthened patent portfolio.
The decision may boost Halozyme's licensing leverage with other pharma partners.
Market effects
May slow adoption of subcutaneous immunotherapy formats in oncology.
European Keytruda SC sales delayed, affecting market share in EU.
Highlights patent risk for biotech collaborations worldwide.
Counterpoint
Investors may view the setback as temporary; Merck's IV Keytruda remains strong.
Key entities
- CompanyMerck
Pharmaceutical giant facing EU patent injunction.
- CompanyHalozyme Therapeutics
Provider of Enhanze subcutaneous delivery technology.
